

ASX Announcement
27 January 2016

Business Update – On Track for Guidance and Continued Growth in 2016

- **Core business on track with continuing growth trajectory**
- **Preliminary revenues for 6 months to 31st December 2015, at \$16.8m, approximately 8% higher than H1 FY2015**
- **Preliminary results indicate profitability in line with guidance, subject to audit, up 50% to approximately \$1.4m for NPAT and approximately \$2.4m for EBITDA (inclusive of medical innovation costs)**
- **Company expects growth trajectory to be maintained in FY2016**
- **Outlook strong with further opportunities to accelerate organic growth and value realisation**

Compumedics Limited (ASX: CMP) is pleased to announce, for the half-year ended 31st December 2015, preliminary results indicate the Company will generate increased profits in line with guidance provided, having shipped and invoiced approximately \$16.8m in sales. Final results will be subject to audit commencing in early February, with the Appendix 4D to be released to the Australian Stock Exchange (ASX) week of February 22nd.

The indicative results reflect the on-going positive outcomes from the Company's continuing process of renewing growth in key markets around the world as well as transforming and relocating key manufacturing activities to lower cost environments. Specifically the Company has also achieved the following milestones in the six months to 31 December 2015:

- US sales orders taken are some 23% higher in USD's H1FY2016 versus H1 FY2015
- New sales person for Sleep and EEG diagnostics in Germany identified and employed, commencing February 2016
- Outsourcing of manufacturing continues with most main product lines to be transferred by April 2016
- Refinancing of the business with Bank of Melbourne completed Christmas Eve with savings to fall to bottom line in H2 FY2016 and beyond.

More detailed analysis and final results will be provided with the release of the Appendix 4D week of February 22nd, 2016.

About Compumedics Limited

Compumedics Limited (ASX: CMP) is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The Company owns US based Neuroscan and Germany based DWL Elektronische GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including Americas; Australia and Asia Pacific; and Europe and the Middle East.

Executive Chairman, Dr David Burton, founded Compumedics in 1987. In the same year the Company successfully designed and installed the first Australian, fully computerised Sleep Clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets. Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards and accolades

including Australia's exporter of the year and has been recognised as a Top 100 Innovator by the both German and Australian Governments.

For further information please contact:

Dr David Burton, Executive Chairman, CEO
Compumedics Limited
T: + 61 3 8420 7300, F: +61 3 8420 7399

Mr David Lawson, Executive Director, CFO
Compumedics Limited
T: + 61 3 8420 7300, F: +61 3 8420 7399

For investor relations and media enquiries please also contact:

Rod North, Managing Director,
Bourse Communications Pty Ltd
T: (03) 9510 8309, M: 0408 670 706
E: rod@boursecommunications.com.au